Reading the tape
NASDAQ: STTK
Shattuck Labs, Inc.
Healthcare · Biotechnology
Market Cap
$313.29M
52w High
$8.33
52w Low
$0.71
P/E
-13.91
Volume
495.35K
Outstanding Shares
47.90M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 554.72%Revenue (TTM): -82.52%FCF (TTM): 34.04%
What changed
The stock rose 554.72% over the last year. Revenue declined 82.52% over the trailing twelve months. Operating margin moved from -1,408.27% to -5,142.7%. Free cash flow grew 34.04% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -5,142.7%. A decisive move in revenue — currently down 82.52% — would be the clearest signal to resolve the ambiguity.
Company profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.
CEOTaylor H. Schreiber
SectorHealthcare
IndustryBiotechnology
Employees44
IPO dateOct 9, 2020
Valuation
Forward P/E—
EV/EBITDA-4.21
Enterprise value$201.38M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin-177.1%▼368.80%vs FY2024
Operating margin-5,142.7%▼265.75%vs FY2024
ROE-59.24%▲37.45%vs FY2024
Analyst consensus
RatingBuy
Target price$16.50▲152.29%
7
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.14 · Revenue est —
View